On July 14, 2026, a new publication concerning elamipretide appeared in the journal Trends in Pharmacological Sciences. The publication is titled "Elamipretide: a mitochondria-targeting drug for Barth syndrome." Elamipretide is an approved compound. This entry reflects the publication of the article as recorded in the scientific literature, identified by PubMed ID 42448476. No findings, outcomes, or conclusions from the article are included in this brief, as that information was not provided. The listing serves to note the appearance of this work in the named journal on the stated date. Readers interested in the details, methodology, or conclusions of this publication should consult the original article directly through the source link provided. This brief does not characterize the content, results, or implications of the study beyond confirming its title, journal, and publication date. For more background on elamipretide, including its regulatory status and general profile, readers can refer to the compound overview.
New Publication on Elamipretide for Barth Syndrome
See the full elamipretide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42448476/